0|chunk|Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir
0	53	56 RNA	Chemical	CHEBI_33697
0	71	81 Remdesivir	Chemical	CHEBI_145994
0	CHEBI-CHEBI	CHEBI_33697	CHEBI_145994

1|chunk|Remdesivir (GS-5734) is a 1 -cyano-substituted adenosine nucleotide analogue prodrug that shows broad-spectrum antiviral activity against several RNA viruses. This compound is currently under clinical development for the treatment of Ebola virus disease (EVD). While antiviral effects have been demonstrated in cell culture and in non-human primates, the mechanism of action of Ebola virus (EBOV) inhibition for remdesivir remains to be fully elucidated. The EBOV RNA-dependent RNA polymerase (RdRp) complex was recently expressed and purified, enabling biochemical studies with the relevant triphosphate (TP) form of remdesivir and its presumptive target. In this study, we confirmed that remdesivir-TP is able to compete for incorporation with adenosine triphosphate (ATP). Enzyme kinetics revealed that EBOV RdRp and respiratory syncytial virus (RSV) RdRp incorporate ATP and remdesivir-TP with similar efficiencies. The selectivity of ATP against remdesivir-TP is~4 for EBOV RdRp and~3 for RSV RdRp. In contrast, purified human mitochondrial RNA polymerase (h-mtRNAP) effectively discriminates against remdesivir-TP with a selectivity value of~500-fold. For EBOV RdRp, the incorporated inhibitor at position i does not affect the ensuing nucleotide incorporation event at position i+1. For RSV RdRp, we measured a~6-fold inhibition at position i+1 although RNA synthesis was not terminated. Chain termination was in both cases delayed and was seen predominantly at position i+5. This pattern is specific to remdesivir-TP and its 1 -cyano modification. Compounds with modifications at the 2 -position show different patterns of inhibition. While 2 -C-methyl-ATP is not incorporated, ara-ATP acts as a non-obligate chain terminator and prevents nucleotide incorporation at position i+1. Taken together, our biochemical data indicate that the major contribution to EBOV RNA synthesis inhibition by remdesivir can be ascribed to delayed chain termination. The long distance of five residues between the incorporated nucleotide analogue and its inhibitory effect warrant further investigation.
1	0	10 Remdesivir	Chemical	CHEBI_145994
1	47	56 adenosine	Chemical	CHEBI_16335
1	57	67 nucleotide	Chemical	CHEBI_36976
1	77	84 prodrug	Chemical	CHEBI_50266
1	111	120 antiviral	Chemical	CHEBI_22587
1	146	149 RNA	Chemical	CHEBI_33697
1	267	276 antiviral	Chemical	CHEBI_22587
1	368	374 action	Chemical	CHEBI_5133
1	412	422 remdesivir	Chemical	CHEBI_145994
1	478	481 RNA	Chemical	CHEBI_33697
1	592	604 triphosphate	Chemical	CHEBI_18036
1	618	628 remdesivir	Chemical	CHEBI_145994
1	746	755 adenosine	Chemical	CHEBI_16335
1	746	768 adenosine triphosphate	Chemical	CHEBI_15422
1	756	768 triphosphate	Chemical	CHEBI_18036
1	871	874 ATP	Chemical	CHEBI_15422
1	939	942 ATP	Chemical	CHEBI_15422
1	1046	1049 RNA	Chemical	CHEBI_33697
1	1190	1199 inhibitor	Chemical	CHEBI_35222
1	1242	1252 nucleotide	Chemical	CHEBI_36976
1	1361	1364 RNA	Chemical	CHEBI_33697
1	1747	1757 nucleotide	Chemical	CHEBI_36976
1	1871	1874 RNA	Chemical	CHEBI_33697
1	1899	1909 remdesivir	Chemical	CHEBI_145994
1	2016	2026 nucleotide	Chemical	CHEBI_36976
1	CHEBI-CHEBI	CHEBI_145994	CHEBI_16335
1	CHEBI-CHEBI	CHEBI_145994	CHEBI_36976
1	CHEBI-CHEBI	CHEBI_145994	CHEBI_50266
1	CHEBI-CHEBI	CHEBI_145994	CHEBI_22587
1	CHEBI-CHEBI	CHEBI_145994	CHEBI_33697
1	CHEBI-CHEBI	CHEBI_145994	CHEBI_5133
1	CHEBI-CHEBI	CHEBI_145994	CHEBI_18036
1	CHEBI-CHEBI	CHEBI_145994	CHEBI_15422
1	CHEBI-CHEBI	CHEBI_145994	CHEBI_35222
1	CHEBI-CHEBI	CHEBI_16335	CHEBI_36976
1	CHEBI-CHEBI	CHEBI_16335	CHEBI_50266
1	CHEBI-CHEBI	CHEBI_16335	CHEBI_22587
1	CHEBI-CHEBI	CHEBI_16335	CHEBI_33697
1	CHEBI-CHEBI	CHEBI_16335	CHEBI_5133
1	CHEBI-CHEBI	CHEBI_16335	CHEBI_18036
1	CHEBI-CHEBI	CHEBI_16335	CHEBI_15422
1	CHEBI-CHEBI	CHEBI_16335	CHEBI_35222
1	CHEBI-CHEBI	CHEBI_36976	CHEBI_50266
1	CHEBI-CHEBI	CHEBI_36976	CHEBI_22587
1	CHEBI-CHEBI	CHEBI_36976	CHEBI_33697
1	CHEBI-CHEBI	CHEBI_36976	CHEBI_5133
1	CHEBI-CHEBI	CHEBI_36976	CHEBI_18036
1	CHEBI-CHEBI	CHEBI_36976	CHEBI_15422
1	CHEBI-CHEBI	CHEBI_36976	CHEBI_35222
1	CHEBI-CHEBI	CHEBI_50266	CHEBI_22587
1	CHEBI-CHEBI	CHEBI_50266	CHEBI_33697
1	CHEBI-CHEBI	CHEBI_50266	CHEBI_5133
1	CHEBI-CHEBI	CHEBI_50266	CHEBI_18036
1	CHEBI-CHEBI	CHEBI_50266	CHEBI_15422
1	CHEBI-CHEBI	CHEBI_50266	CHEBI_35222
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_33697
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_5133
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_18036
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_15422
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_35222
1	CHEBI-CHEBI	CHEBI_33697	CHEBI_5133
1	CHEBI-CHEBI	CHEBI_33697	CHEBI_18036
1	CHEBI-CHEBI	CHEBI_33697	CHEBI_15422
1	CHEBI-CHEBI	CHEBI_33697	CHEBI_35222
1	CHEBI-CHEBI	CHEBI_5133	CHEBI_18036
1	CHEBI-CHEBI	CHEBI_5133	CHEBI_15422
1	CHEBI-CHEBI	CHEBI_5133	CHEBI_35222
1	CHEBI-CHEBI	CHEBI_18036	CHEBI_15422
1	CHEBI-CHEBI	CHEBI_18036	CHEBI_35222
1	CHEBI-CHEBI	CHEBI_15422	CHEBI_35222

2|chunk|Viruses 2019, 11, 326 2 of 16 two single-stranded genome fragments such as the Arenaviridae (e.g., LASV), three fragments such as the order Bunyavirals (formerly the family Bunyaviridae, e.g., CCHFV), or multiple fragments such as the Orthomyxoviridae (e.g., influenza). Examples of families of non-segmented negative-sense RNA viruses with a single-stranded RNA genome (Mononegavirales) include the Filoviridae (e.g., EBOV), the Paramyxoviridae (e.g., Nipah virus (NiV)), and the Pneumoviridae (e.g., RSV).
2	324	327 RNA	Chemical	CHEBI_33697
2	359	362 RNA	Chemical	CHEBI_33697

3|chunk|Prevention and treatment of infection with negative-sense RNA viruses remain challenging. The 2014 Ebola virus disease (EVD) outbreak in West Africa caused approximately 28,000 cases and 11,310 deaths and is a sober reminder of an unmet medical need [2] . Intensive research efforts during that outbreak led to the discovery and development of several vaccine and drug candidates. Promising experimental vaccines against EBOV are based on the envelope glycoprotein as the antigenic target [3] . Monoclonal antibodies and nucleotide analogue inhibitors represent investigational therapies. ZMapp, a cocktail of three monoclonal antibodies that target the EBOV glycoprotein [4] , was shown to reverse EVD in non-human primates [5] . However, results from a randomized clinical trial were inconclusive [6] . Like glycoprotein-based vaccines, the antibody cocktail is also not effective against all ebolavirus species [7, 8] . In contrast, several nucleotide analogues show antiviral activity against different ebolavirus species and also other negative-and positive-sense RNA viruses [9] [10] [11] [12] [13] [14] [15] [16] [17] .
3	58	61 RNA	Chemical	CHEBI_33697
3	364	368 drug	Chemical	CHEBI_23888
3	452	464 glycoprotein	Chemical	CHEBI_17089
3	521	531 nucleotide	Chemical	CHEBI_36976
3	541	551 inhibitors	Chemical	CHEBI_35222
3	659	671 glycoprotein	Chemical	CHEBI_17089
3	944	954 nucleotide	Chemical	CHEBI_36976
3	970	979 antiviral	Chemical	CHEBI_22587
3	1069	1072 RNA	Chemical	CHEBI_33697
3	CHEBI-CHEBI	CHEBI_33697	CHEBI_23888
3	CHEBI-CHEBI	CHEBI_33697	CHEBI_17089
3	CHEBI-CHEBI	CHEBI_33697	CHEBI_36976
3	CHEBI-CHEBI	CHEBI_33697	CHEBI_35222
3	CHEBI-CHEBI	CHEBI_33697	CHEBI_22587
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_17089
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_36976
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_35222
3	CHEBI-CHEBI	CHEBI_23888	CHEBI_22587
3	CHEBI-CHEBI	CHEBI_17089	CHEBI_36976
3	CHEBI-CHEBI	CHEBI_17089	CHEBI_35222
3	CHEBI-CHEBI	CHEBI_17089	CHEBI_22587
3	CHEBI-CHEBI	CHEBI_36976	CHEBI_35222
3	CHEBI-CHEBI	CHEBI_36976	CHEBI_22587
3	CHEBI-CHEBI	CHEBI_35222	CHEBI_22587

4|chunk|Favipiravir (T-705) is a nucleoside precursor that has been approved for treatment of pandemic influenza in Japan [14, 18, 19] . Intracellular phosphoribosylation yields a triphosphate form (T-705-RTP) that is accommodated by the viral RNA-dependent RNA polymerase (RdRp) (Figure 1) [20]. Experiments with recombinant influenza RdRp show ambiguous base-pairing with both cytidine and uridine, which can lead to lethal mutagenesis [21] . Incorporation of the T-705-RTP into the growing RNA chain can also cause moderate inhibition of RNA synthesis. Favipiravir is active against a large panel of RNA viruses in vitro, including EBOV [12, 22, 23] . The clinical evaluation has been challenging and results of a multicenter non-randomized trial were largely inconclusive [24] . The structure of the base moiety and proposed mechanism of action are reminiscent of ribavirin that has been used for over a decade to treat infection with the hepatitis C virus (HCV) (Figure 1 ) [25] [26] [27] [28] . A structurally distinct broad-spectrum antiviral agent that is also active against EBOV in vitro is galidesivir (BCX4430) [11] . Galidesivir is an adenosine-like compound with a nitrogen-substituted sugar ring that likewise requires intracellular activation to the TP form (Figure 1) . Biochemical experiments show that this compound serves as a substrate for the RdRp of HCV and causes chain termination following its incorporation [11] .
4	0	11 Favipiravir	Chemical	CHEBI_134722
4	23	35 a nucleoside	Chemical	CHEBI_33838
4	25	35 nucleoside	Chemical	CHEBI_33838
4	172	184 triphosphate	Chemical	CHEBI_18036
4	250	253 RNA	Chemical	CHEBI_33697
4	371	379 cytidine	Chemical	CHEBI_17562
4	485	488 RNA	Chemical	CHEBI_33697
4	533	536 RNA	Chemical	CHEBI_33697
4	548	559 Favipiravir	Chemical	CHEBI_134722
4	595	598 RNA	Chemical	CHEBI_33697
4	834	840 action	Chemical	CHEBI_5133
4	860	869 ribavirin	Chemical	CHEBI_63580
4	1032	1041 antiviral	Chemical	CHEBI_22587
4	1032	1047 antiviral agent	Chemical	CHEBI_22587
4	CHEBI-CHEBI	CHEBI_134722	CHEBI_33838
4	CHEBI-CHEBI	CHEBI_134722	CHEBI_18036
4	CHEBI-CHEBI	CHEBI_134722	CHEBI_33697
4	CHEBI-CHEBI	CHEBI_134722	CHEBI_17562
4	CHEBI-CHEBI	CHEBI_134722	CHEBI_5133
4	CHEBI-CHEBI	CHEBI_134722	CHEBI_63580
4	CHEBI-CHEBI	CHEBI_134722	CHEBI_22587
4	CHEBI-CHEBI	CHEBI_33838	CHEBI_18036
4	CHEBI-CHEBI	CHEBI_33838	CHEBI_33697
4	CHEBI-CHEBI	CHEBI_33838	CHEBI_17562
4	CHEBI-CHEBI	CHEBI_33838	CHEBI_5133
4	CHEBI-CHEBI	CHEBI_33838	CHEBI_63580
4	CHEBI-CHEBI	CHEBI_33838	CHEBI_22587
4	CHEBI-CHEBI	CHEBI_18036	CHEBI_33697
4	CHEBI-CHEBI	CHEBI_18036	CHEBI_17562
4	CHEBI-CHEBI	CHEBI_18036	CHEBI_5133
4	CHEBI-CHEBI	CHEBI_18036	CHEBI_63580
4	CHEBI-CHEBI	CHEBI_18036	CHEBI_22587
4	CHEBI-CHEBI	CHEBI_33697	CHEBI_17562
4	CHEBI-CHEBI	CHEBI_33697	CHEBI_5133
4	CHEBI-CHEBI	CHEBI_33697	CHEBI_63580
4	CHEBI-CHEBI	CHEBI_33697	CHEBI_22587
4	CHEBI-CHEBI	CHEBI_17562	CHEBI_5133
4	CHEBI-CHEBI	CHEBI_17562	CHEBI_63580
4	CHEBI-CHEBI	CHEBI_17562	CHEBI_22587
4	CHEBI-CHEBI	CHEBI_5133	CHEBI_63580
4	CHEBI-CHEBI	CHEBI_5133	CHEBI_22587
4	CHEBI-CHEBI	CHEBI_63580	CHEBI_22587

5|chunk|Remdesivir (GS-5734) is a phosphoramidate prodrug of a 1 -cyano-substitued adenosine analogue that inhibits ebolaviruses with half maximal effective concentrations (EC 50 ) in the submicromolar range [9,10], which is considerably lower than the values reported for favipiravir or galidesivir [11, 13, 29, 30] . The triphosphate form of remdesivir (remdesivir-TP) was shown to inhibit the RSV RdRp surrogate for EBOV RdRp [10]. No significant inhibition was seen with human RNA Pol II and human mitochondrial RNA polymerase (h-mtRNAP) [10] . The biochemical data obtained with purified recombinant RSV RdRp and a recent study with NiV RdRp point to delayed chain termination as a possible mechanism of action [10, 31] . Delayed chain termination refers to inhibition of RNA synthesis a few residues downstream of the incorporated inhibitor. However, the inhibition results have yet to be translated in quantitative terms and data with recombinant EBOV RdRp are lacking. RSV, NiV, and EBOV are non-segmented viruses that share similar requirements for RNA synthesis [32, 33] . RdRp activity of RSV and NiV requires the multifunctional L protein and the phosphoprotein or P protein [31, 34, 35] . While the L protein contains the polymerase active site, the P protein is necessary to form an active complex [36] . We have recently expressed active EBOV RdRp that contains the L protein in complex with viral protein 35 (VP35) [33] , which is the functional equivalent of P proteins [37] . In this study, we utilized the EBOV RdRp complex to study the mechanism of action of remdesivir. We demonstrate that incorporation of the nucleotide analogue at position i causes delayed chain termination predominantly at position i+5. Author Contributions: Individual contributions are as follows: conceptualization, M.G. and E.P.T.; methodology, E.P.T.; software, E.P.T.; validation, M.G. and E.P.T.; formal analysis, M.G., J.Y.F., D.P.P., and E.P.T.; investigation, E.P.T.; resources, M.G.; data curation, M.G. and E.P.T.; writing-original draft preparation, M.G.; writing-review and editing, M.G., J.Y.F., D.P.P., and E.P.T.; visualization, E.P.T.; supervision, M.G.; project administration, M.G.; funding acquisition, M.G.
5	0	10 Remdesivir	Chemical	CHEBI_145994
5	26	41 phosphoramidate	Chemical	CHEBI_29920
5	42	49 prodrug	Chemical	CHEBI_50266
5	75	84 adenosine	Chemical	CHEBI_16335
5	265	276 favipiravir	Chemical	CHEBI_134722
5	315	327 triphosphate	Chemical	CHEBI_18036
5	336	346 remdesivir	Chemical	CHEBI_145994
5	473	476 RNA	Chemical	CHEBI_33697
5	508	511 RNA	Chemical	CHEBI_33697
5	701	707 action	Chemical	CHEBI_5133
5	769	772 RNA	Chemical	CHEBI_33697
5	1050	1053 RNA	Chemical	CHEBI_33697
5	1135	1142 protein	Chemical	CHEBI_16541
5	1171	1178 protein	Chemical	CHEBI_16541
5	1206	1213 protein	Chemical	CHEBI_16541
5	1257	1264 protein	Chemical	CHEBI_16541
5	1375	1382 protein	Chemical	CHEBI_16541
5	1405	1412 protein	Chemical	CHEBI_16541
5	1470	1478 proteins	Chemical	CHEBI_36080
5	1561	1567 action	Chemical	CHEBI_5133
5	1571	1581 remdesivir	Chemical	CHEBI_145994
5	1624	1634 nucleotide	Chemical	CHEBI_36976
5	CHEBI-CHEBI	CHEBI_145994	CHEBI_29920
5	CHEBI-CHEBI	CHEBI_145994	CHEBI_50266
5	CHEBI-CHEBI	CHEBI_145994	CHEBI_16335
5	CHEBI-CHEBI	CHEBI_145994	CHEBI_134722
5	CHEBI-CHEBI	CHEBI_145994	CHEBI_18036
5	CHEBI-CHEBI	CHEBI_145994	CHEBI_33697
5	CHEBI-CHEBI	CHEBI_145994	CHEBI_5133
5	CHEBI-CHEBI	CHEBI_145994	CHEBI_16541
5	CHEBI-CHEBI	CHEBI_145994	CHEBI_36080
5	CHEBI-CHEBI	CHEBI_145994	CHEBI_36976
5	CHEBI-CHEBI	CHEBI_29920	CHEBI_50266
5	CHEBI-CHEBI	CHEBI_29920	CHEBI_16335
5	CHEBI-CHEBI	CHEBI_29920	CHEBI_134722
5	CHEBI-CHEBI	CHEBI_29920	CHEBI_18036
5	CHEBI-CHEBI	CHEBI_29920	CHEBI_33697
5	CHEBI-CHEBI	CHEBI_29920	CHEBI_5133
5	CHEBI-CHEBI	CHEBI_29920	CHEBI_16541
5	CHEBI-CHEBI	CHEBI_29920	CHEBI_36080
5	CHEBI-CHEBI	CHEBI_29920	CHEBI_36976
5	CHEBI-CHEBI	CHEBI_50266	CHEBI_16335
5	CHEBI-CHEBI	CHEBI_50266	CHEBI_134722
5	CHEBI-CHEBI	CHEBI_50266	CHEBI_18036
5	CHEBI-CHEBI	CHEBI_50266	CHEBI_33697
5	CHEBI-CHEBI	CHEBI_50266	CHEBI_5133
5	CHEBI-CHEBI	CHEBI_50266	CHEBI_16541
5	CHEBI-CHEBI	CHEBI_50266	CHEBI_36080
5	CHEBI-CHEBI	CHEBI_50266	CHEBI_36976
5	CHEBI-CHEBI	CHEBI_16335	CHEBI_134722
5	CHEBI-CHEBI	CHEBI_16335	CHEBI_18036
5	CHEBI-CHEBI	CHEBI_16335	CHEBI_33697
5	CHEBI-CHEBI	CHEBI_16335	CHEBI_5133
5	CHEBI-CHEBI	CHEBI_16335	CHEBI_16541
5	CHEBI-CHEBI	CHEBI_16335	CHEBI_36080
5	CHEBI-CHEBI	CHEBI_16335	CHEBI_36976
5	CHEBI-CHEBI	CHEBI_134722	CHEBI_18036
5	CHEBI-CHEBI	CHEBI_134722	CHEBI_33697
5	CHEBI-CHEBI	CHEBI_134722	CHEBI_5133
5	CHEBI-CHEBI	CHEBI_134722	CHEBI_16541
5	CHEBI-CHEBI	CHEBI_134722	CHEBI_36080
5	CHEBI-CHEBI	CHEBI_134722	CHEBI_36976
5	CHEBI-CHEBI	CHEBI_18036	CHEBI_33697
5	CHEBI-CHEBI	CHEBI_18036	CHEBI_5133
5	CHEBI-CHEBI	CHEBI_18036	CHEBI_16541
5	CHEBI-CHEBI	CHEBI_18036	CHEBI_36080
5	CHEBI-CHEBI	CHEBI_18036	CHEBI_36976
5	CHEBI-CHEBI	CHEBI_33697	CHEBI_5133
5	CHEBI-CHEBI	CHEBI_33697	CHEBI_16541
5	CHEBI-CHEBI	CHEBI_33697	CHEBI_36080
5	CHEBI-CHEBI	CHEBI_33697	CHEBI_36976
5	CHEBI-CHEBI	CHEBI_5133	CHEBI_16541
5	CHEBI-CHEBI	CHEBI_5133	CHEBI_36080
5	CHEBI-CHEBI	CHEBI_5133	CHEBI_36976
5	CHEBI-CHEBI	CHEBI_16541	CHEBI_36080
5	CHEBI-CHEBI	CHEBI_16541	CHEBI_36976
5	CHEBI-CHEBI	CHEBI_36080	CHEBI_36976

